KR20230054431A - 오토파지 활성화제 - Google Patents

오토파지 활성화제 Download PDF

Info

Publication number
KR20230054431A
KR20230054431A KR1020237009525A KR20237009525A KR20230054431A KR 20230054431 A KR20230054431 A KR 20230054431A KR 1020237009525 A KR1020237009525 A KR 1020237009525A KR 20237009525 A KR20237009525 A KR 20237009525A KR 20230054431 A KR20230054431 A KR 20230054431A
Authority
KR
South Korea
Prior art keywords
methylhesperidin
autophagy
gene
salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009525A
Other languages
English (en)
Korean (ko)
Inventor
유코 나카가미
Original Assignee
가부시끼가이샤 레조낙
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시끼가이샤 레조낙 filed Critical 가부시끼가이샤 레조낙
Publication of KR20230054431A publication Critical patent/KR20230054431A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237009525A 2020-09-17 2021-09-17 오토파지 활성화제 Pending KR20230054431A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-156459 2020-09-17
JP2020156459 2020-09-17
PCT/JP2021/034285 WO2022059775A1 (ja) 2020-09-17 2021-09-17 オートファジー活性化剤

Publications (1)

Publication Number Publication Date
KR20230054431A true KR20230054431A (ko) 2023-04-24

Family

ID=80776133

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009525A Pending KR20230054431A (ko) 2020-09-17 2021-09-17 오토파지 활성화제

Country Status (6)

Country Link
US (1) US20230355646A1 (https=)
EP (1) EP4215199A4 (https=)
JP (1) JPWO2022059775A1 (https=)
KR (1) KR20230054431A (https=)
CN (1) CN116322705B (https=)
WO (1) WO2022059775A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022159546A (ja) * 2022-08-22 2022-10-17 功 加治佐 オートファジーとサーチュインとｉＰＳウイルス運び屋若返り不老不死薬１０

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510902A (ja) 2015-04-08 2018-04-19 バイオメンディクス エルエルシー 創傷治癒調節のための製剤および方法
JP2018080204A (ja) 2011-08-01 2018-05-24 株式会社林原 α−グルコシルヘスペリジンの結晶とその用途
WO2018173653A1 (ja) 2017-03-24 2018-09-27 株式会社林原 オートファジー誘導剤とその用途
JP2019529514A (ja) 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944375A (ja) 1982-09-06 1984-03-12 Senjiyu Seiyaku Kk α−トコフエロ−ルリン酸エステルの安定な水溶液
US4654869A (en) 1985-09-11 1987-03-31 Itt Corporation Information collecting and forwarding apparatus
JPH0649715B2 (ja) 1987-02-10 1994-06-29 栗田工業株式会社 末端にイノシト−ル残基を結合したグルコオリゴ糖およびその製造方法
JPH0730066B2 (ja) 1988-03-09 1995-04-05 株式会社日本ハイポックス アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤
JP2747001B2 (ja) 1989-04-18 1998-05-06 昭和電工株式会社 Ｌ―アスコルビン酸―２―リン酸エステル類の製造法
JP2926412B2 (ja) 1989-05-19 1999-07-28 株式会社林原生物化学研究所 α―グリコシル―Ｌ―アスコルビン酸とその製造方法並びに用途
JPH06298783A (ja) 1993-03-31 1994-10-25 Mitsui Toatsu Chem Inc 新規なグリコシドの製造法
JP2705512B2 (ja) 1993-06-04 1998-01-28 昭和電工株式会社 Ｌ−アスコルビン酸−２−リン酸エステルの製造方法
JPH08134055A (ja) 1994-11-08 1996-05-28 Nippon High Potsukusu:Kk ３−ｏ−置換アスコルビン酸の製造方法
JPH0914705A (ja) 1995-06-29 1997-01-17 Hitachi Ltd 流体移送装置
KR20040065864A (ko) * 2003-01-16 2004-07-23 주식회사 엘지생활건강 피부알러지 완화 및 예방용 조성물
WO2010119955A1 (ja) * 2009-04-17 2010-10-21 ロート製薬株式会社 アドバンスド・グリケーション・エンド・プロダクツの蓄積による肌の老化の予防、抑制、又は改善剤
JP5735254B2 (ja) * 2009-10-22 2015-06-17 花王株式会社 経口紫外線抵抗性向上剤
JP6116869B2 (ja) * 2012-01-17 2017-04-19 花王株式会社 経口紫外線抵抗性向上剤
JP6312333B2 (ja) 2013-05-10 2018-04-18 昭和電工株式会社 糖化反応抑制剤
WO2016076310A1 (ja) 2014-11-10 2016-05-19 昭和電工株式会社 保湿剤
JP6832113B2 (ja) * 2016-09-30 2021-02-24 小林製薬株式会社 医薬組成物
CA3059461C (en) * 2017-04-12 2023-08-15 Glovia Company Limited Composition for treatment and/or prevention of alzheimer's disease
CN111051519B (zh) 2017-09-04 2024-04-26 株式会社力森诺科 肌醇衍生物的混合物
JP2020125246A (ja) * 2019-02-01 2020-08-20 花王株式会社 認知機能障害改善剤
CN110024706A (zh) 2019-03-25 2019-07-19 嘉兴市顶升杯业有限公司 一种新型宠物碗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080204A (ja) 2011-08-01 2018-05-24 株式会社林原 α−グルコシルヘスペリジンの結晶とその用途
JP2018510902A (ja) 2015-04-08 2018-04-19 バイオメンディクス エルエルシー 創傷治癒調節のための製剤および方法
JP2019529514A (ja) 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
WO2018173653A1 (ja) 2017-03-24 2018-09-27 株式会社林原 オートファジー誘導剤とその用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Aaron Barnett et al., Autophagy in Aging and Alzheimer's Disease: Pathologic or Protective?. J Alzheimers Dis. 2011; 25(3): 385-394.
Gowrikumar Saiprasad et al., Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis. European Journal of Cancer (2014) 50, 2489-2507.
Marta M. Lipinski et al., Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci USA. 2010, 107, 14164-14169.
Xiangqing Li et al., Cubeben induces autophagy via PI3K-AKT-mTOR pathway to protect primary neurons against amyloid beta in Alzheimer's disease. Cytotechnology (2019) 71: 679-686.
Yogendra S. Rajawat et al., Aging: Central role for autophagy and the lysosomal degradative system. Ageing Research Reviews 8 (2009) 199-213.
이노마타 외, 「오토파지와 노화의 관련성」, 기후켄 치과학회 잡지, 2018년, 제45권, 제1호, 1-7
카게야마 외, 「오토파지와 질환」, 영역 융합 리뷰, 2014년, 3, e006

Also Published As

Publication number Publication date
CN116322705B (zh) 2025-10-10
JPWO2022059775A1 (https=) 2022-03-24
WO2022059775A1 (ja) 2022-03-24
US20230355646A1 (en) 2023-11-09
EP4215199A4 (en) 2024-10-09
EP4215199A1 (en) 2023-07-26
CN116322705A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
KR101154616B1 (ko) 캄페롤 및 퀘르세틴을 함유하는 히알루론산 생성 촉진용조성물
JPWO2006126675A1 (ja) 皮膚外用剤
KR20150032143A (ko) 로즈마리 추출물 및 아세트산레티놀을 포함하는 히알루론산 분해 억제제
US10918585B2 (en) Anti-aging agent and anti-aging composition for skin
TWI790238B (zh) 含有葉黃素類或其鹽及菱屬植物加工物之腦之錐體細胞的減少抑制劑
KR20230054431A (ko) 오토파지 활성화제
JPH11323326A (ja) 活性酸素消去剤、皮膚保全剤および変色防止剤
KR20230051237A (ko) 오토파지 활성화제
EP3636266A1 (en) Agent for inhibiting skin trouble and composition for inhibiting skin trouble
JP5657723B2 (ja) 皮膚光老化の予防又は抑制剤
JP5703313B2 (ja) ３−ヒドロキシ−２−ピロンを含有する美白剤
KR20230051238A (ko) 오토파지 활성화제
TWI844795B (zh) 自噬活化劑
JP2007056219A (ja) 抗酸化組成物
KR20170099674A (ko) 피부 개선용 조성물
KR20170025370A (ko) 피부 개선용 조성물
KR20170025359A (ko) 피부 개선용 조성물
HK40006005A (en) Association and methods for fighting against the signs of ageing
KR20170099658A (ko) 피부 개선용 조성물
KR20170099671A (ko) 피부 개선용 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000